Evidence map›Paper›PMID 32056090›Full record

Observational studyDigestive diseases and sciences2021

Patterns and Outcomes in Hepatocellular Carcinoma Patients with Portal Vein Invasion: A Multicenter Prospective Cohort Study.

Dong Hyun Sinn, Hye Won Lee, Yong-Han Paik, Do Young Kim, Yoon Jun Kim, Kang Mo Kim, Si Hyun Bae, Ji Hoon Kim, Yeon Seok Seo, Jae Young Jang and 9 more

Open access · greenAbstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Digestive diseases and sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Guideline
  2. Review
  3. Hepatic Expression of NTN4 and Its Receptors in Patients with Hepatocellular Carcinoma.Asian Pacific journal of cancer prevention : APJCP · 2023
    Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 13 institutions in 1 country.

Dong Hyun SinnDepartment of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, South Korea.
Hye Won LeeDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
Yong-Han PaikDepartment of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, South Korea. yh.paik@skku.edu.ORCID 0000-0002-3076-2327
Do Young KimDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
Yoon Jun KimDepartment of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
Kang Mo KimDepartment of Internal Medicine, University of Ulsan College of Medicine, Seoul, South Korea.
Si Hyun BaeDepartment of Internal Medicine, The Catholic University of Korea, Seoul, South Korea.
Ji Hoon KimDepartment of Internal Medicine, Korea University College of Medicine, Seoul, South Korea.
Yeon Seok SeoDepartment of Internal Medicine, Korea University College of Medicine, Seoul, South Korea.
Jae Young JangDepartment of Internal Medicine, Soonchunhyang University, Seoul, South Korea.
Byoung Kuk JangDepartment of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea.
Hyung Joon YimDepartment of Internal Medicine, Korea University College of Medicine, Seoul, South Korea.
Hyung Joon KimDepartment of Internal Medicine, Chung-Ang University College of Medicine, Seoul, South Korea.
Byung Seok LeeDepartment of Internal Medicine, Chungnam University College of Medicine, Daejeon, South Korea.
Bo Hyun KimCenter for Liver Cancer, National Cancer Center, Goyang, South Korea.
In Hee KimDepartment of Internal Medicine, Chonbuk National University, Chonju, South Korea.
Eun-Young ChoDepartment of Internal Medicine, Wonkwang University College of Medicine, Iksan, South Korea.
Jung Il LeeDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
Kyung-Suk SuhDepartment of Surgery, Seoul National University College of Medicine, Seoul, South Korea.
Korea University · KRSeoul National University · KRSamsung Medical Center · KRYonsei University · KRCatholic University of Korea · KRChung-Ang University · KRChungnam National University · KRJeonbuk National University · KRKeimyung University · KRNational Cancer Center · KRSoonchunhyang University · KRUlsan College · KRWonkwang University · KR

Funding

Korean Liver Cancer Association 2016 Study Grant
6 · The paper itself

Abstract

BACKGROUND AND

aimsSorafenib is a proven first-line treatment recommended for hepatocellular carcinoma (HCC) patients with portal vein invasion (PVI). However, multiple treatment modalities are used in clinical practice as a first-line option. This study is a prospective, observational, multicenter, cohort study evaluating patterns of treatment modalities and outcomes for HCC patients with PVI.

methodsThe baseline characteristics, treatment modalities, and outcomes were prospectively collected for 287 newly diagnosed HCC patients with PVI between August 2015 and July 2016 from 16 sites in Korea.

resultsDuring a median 7.8 months of follow-up (range 0.3-24.6 months), mortality was observed in 123 (42.9%) patients. Decision tree analysis classified patients into five subgroups with different outcomes. The patterns of treatment were very heterogeneous, and there was no dominant treatment modality. The most commonly used treatment modality was transarterial chemoembolization (TACE) (20.2%) followed by TACE plus external beam radiation therapy (17.8%) and sorafenib (12.5%). When stratified according to the extent of PVI, sorafenib treatment showed comparable outcomes when the PVI extent was lobal or main/bilateral, yet showed worse outcomes when the PVI extent was limited to the segmental level compared to those who received treatment other than sorafenib.

conclusionsHCC patients with PVI comprise a heterogeneous population and are treated with various treatment modalities with diverse clinical outcomes in clinical practice. Subclassification of HCC patients with PVI is required to minimize heterogeneity and should be considered for the selection of treatment modalities and future clinical trials.

Indexed as

AgedAntineoplastic AgentsCarcinoma, HepatocellularChemoembolization, TherapeuticCohort StudiesCombined Modality TherapyFemaleFollow-Up StudiesHumansLiver NeoplasmsMaleMiddle AgedNeoplasm InvasivenessPortal VeinProspective StudiesSorafenibAntineoplastic AgentsSorafenibCohortHepatocellular carcinomaPortal vein invasion

Identifiers

PMID32056090
OpenAlexW3006590314

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.